Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Director G Bradley Cole Sells 3,673 Shares

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Director G Bradley Cole sold 3,673 shares of the stock in a transaction on Wednesday, July 29th. The stock was sold at an average price of $81.43, for a total value of $299,092.39. Following the transaction, the director directly owned 11,672 shares in the company, valued at $950,450.96. The trade was a 23.94% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Kiniksa Pharmaceuticals International Stock Performance

NASDAQ KNSA opened at $74.34 on Friday. Kiniksa Pharmaceuticals International, plc has a one year low of $29.90 and a one year high of $82.94. The company has a market capitalization of $5.72 billion, a price-to-earnings ratio of 76.64 and a beta of 0.07. The company’s 50-day simple moving average is $59.04 and its two-hundred day simple moving average is $51.13.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last announced its quarterly earnings results on Tuesday, July 28th. The company reported $0.30 earnings per share for the quarter, hitting the consensus estimate of $0.30. Kiniksa Pharmaceuticals International had a net margin of 9.59% and a return on equity of 13.65%. The firm had revenue of $243.60 million during the quarter, compared to analysts’ expectations of $226.49 million. Equities analysts expect that Kiniksa Pharmaceuticals International, plc will post 1.38 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the company. Canaccord Genuity Group upped their target price on Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the stock a “buy” rating in a report on Wednesday. Zacks Research upgraded Kiniksa Pharmaceuticals International from a “hold” rating to a “strong-buy” rating in a report on Wednesday, June 17th. Weiss Ratings raised Kiniksa Pharmaceuticals International from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday. The Goldman Sachs Group upped their price objective on Kiniksa Pharmaceuticals International from $75.00 to $90.00 and gave the stock a “buy” rating in a research note on Thursday. Finally, Wells Fargo & Company raised their price objective on Kiniksa Pharmaceuticals International from $57.00 to $74.00 and gave the company an “overweight” rating in a research report on Monday, July 13th. One research analyst has rated the stock with a Strong Buy rating and nine have issued a Buy rating to the company. According to MarketBeat, Kiniksa Pharmaceuticals International presently has an average rating of “Buy” and a consensus target price of $87.38.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of KNSA. EverSource Wealth Advisors LLC grew its holdings in shares of Kiniksa Pharmaceuticals International by 140.4% during the second quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock valued at $25,000 after buying an additional 532 shares during the last quarter. Osaic Holdings Inc. acquired a new stake in Kiniksa Pharmaceuticals International during the 2nd quarter worth about $31,000. KBC Group NV purchased a new stake in Kiniksa Pharmaceuticals International during the 1st quarter valued at about $34,000. Smartleaf Asset Management LLC purchased a new stake in Kiniksa Pharmaceuticals International during the 4th quarter valued at about $36,000. Finally, Nano Cap New Millennium Growth Fund L P acquired a new position in shares of Kiniksa Pharmaceuticals International in the fourth quarter valued at about $41,000. Institutional investors own 53.95% of the company’s stock.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.